3+ day, 17+ hour ago   (413+ words) AllSci Cambridge, UK-based ViaNautis Bio has secured investment from SCI Ventures to expand its non-viral genetic medicine delivery platform into chronic spinal cord injury (CSI). Financial terms of the investment were not disclosed. SCI Ventures describes itself as a mission-driven…...

4+ day, 15+ hour ago   (344+ words) allsci.com San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and France-based Servier announced that the first patient has been dosed in OptimUM-11, a global Phase III registrational trial evaluating darovasertib in combination with crizotinib as adjuvant therapy for patients with primary…...

5+ day, 18+ hour ago   (440+ words) AllSci Seattle-based BrainChild Bio, Inc., a clinical-stage company developing CAR T cell therapies for central nervous system tumors, has closed a USD 116 million Series A financing to fund a pivotal registrational trial in diffuse intrinsic pontine glioma (DIPG), a uniformly…...

1+ week, 4+ day ago   (398+ words) AllSci Positive Phase II data for GSK's mRNA seasonal influenza vaccine candidate FLUm3HA.b-3NA have cleared the bar for a Phase III efficacy trial, with the UK giant reporting higher immune responses against all tested influenza strains compared to both standard-dose and…...

1+ week, 5+ day ago   (577+ words) AllSci Eli Lilly has agreed to acquire Cambridge, Massachusetts-based Merida Biosciences, Inc., a private precision immunology company, for up to USD 2.875 billion in cash, adding a precision immunology platform led by the Phase I antibody therapeutic MER511, designed to selectively deplete…...

3+ week, 2+ day ago   (117+ words) CStone said preclinical studies showed CS5007 had antitumor activity across models with different levels of EGFR and HER3 expression. Its ability to differentiate clinically from iza-bren and other ADCs targeting EGFR-family receptors will depend on the therapeutic window generated by its antibody,…...